Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

References

• Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis. 2012;206(2):275–282.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Fuchs D, Svennerholm B, et al. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21(4):271–276.
   PubMed Web of Science ®Google Scholar
• Williams KC, Hickey WF. Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci. 2002;25(1):537–562.
   PubMedGoogle Scholar
• Mellgren Å, Antinori A, Cinque P, et al. Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (Lond). 2005;10(6):701–707.
   PubMed Web of Science ®Google Scholar
• Edén A, Price RW, Spudich S, et al. Immune activation of the central nervous system is still present after 4 years of effective highly active antiretroviral therapy. J Infect Dis. 2007;196(12):1779–1783.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Yiannoutsos CT, Fuchs D, et al. Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation. 2013;10(1):62.
   PubMedGoogle Scholar
• Krut JJ, Mellberg T, Price RW, et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One. 2014;9(2):e88591
   PubMed Web of Science ®Google Scholar
• Abdulle S, Mellgren A, Brew BJ, et al. CSF neurofilament protein (NFL) – a marker of active HIV-related neurodegeneration. J Neurol. 2007;254(8):1026–1032.
   PubMed Web of Science ®Google Scholar
• Mellgren Å, Price RW, Hagberg L, et al. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology. 2007;69(15):1536–1541.
   PubMed Web of Science ®Google Scholar
• Peterson J, Gisslen M, Zetterberg H, et al. Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One. 2014;9(12):e116081.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Price RW, Andreasson U, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;22:135–140.
   Google Scholar
• Yilmaz A, Blennow K, Hagberg L, et al. Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn. 2017;17(8):761–770.
   PubMed Web of Science ®Google Scholar
• Eriksen J, Albert J, Blaxhult A, et al. Antiretroviral treatment for HIV infection: Swedish recommendations 2016. Infect Dis (Auckl). 2017;49(1):1–34.
   PubMed Web of Science ®Google Scholar
• Bam RA, Birkus G, Babusis D, et al. Metabolism and antiretroviral activity of tenofovir alafenamide in CD4+ T-cells and macrophages from demographically diverse donors. Antivir Ther. 2014;19(7):669–677.
   PubMed Web of Science ®Google Scholar
• Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49(5):1898–1906.
   PubMed Web of Science ®Google Scholar
• Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother. 2012;56(10):5409–5413.
   PubMed Web of Science ®Google Scholar
• Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2004;349(21):1993–2003.
   Web of Science ®Google Scholar
• Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371(9622):1417–1426.
   PubMed Web of Science ®Google Scholar
• Ribaudo HJ, Benson CA, Zheng Y, et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clin Infect Dis. 2011;52(7):929–940.
   PubMed Web of Science ®Google Scholar
• Elion RA, Althoff KN, Zhang J, et al. Recent abacavir use increases risk for Types 1 and 2 myocardial infarctions among adults with HIV. JAIDS J Acquir Immune Defic Syndr. 2018;78(1):62–72.
   PubMed Web of Science ®Google Scholar
• Alvarez A, Rios-Navarro C, Blanch-Ruiz MA, et al. Abacavir induces platelet-endothelium interactions by interfering with purinergic signalling: a step from inflammation to thrombosis. Antiviral Res. 2017;141:179–185.
   PubMed Web of Science ®Google Scholar
• Padilla SS, Masiá M, García N, et al. Early changes in inflammatory and pro-thrombotic biomarkers in patients initiating antiretroviral therapy with abacavir or tenofovir. BMC Infect Dis. 2011;11(1):40.
   PubMedGoogle Scholar
• McComsey GA, Kitch D, Daar ES, et al. Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS. 2012;26(11):1371–1385.
   PubMed Web of Science ®Google Scholar
• Capparelli EV, Letendre SL, Ellis RJ, et al. Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother. 2005;49(6):2504–2506.
   PubMed Web of Science ®Google Scholar
• Robertson K, Liner J, Meeker RB. Antiretroviral neurotoxicity. J Neurovirol. 2012;18(5):388–399.
   PubMed Web of Science ®Google Scholar
• Gisslén M, Hagberg L, Brew BJ, et al. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis. 2007;195(12):1774–1778.
   PubMed Web of Science ®Google Scholar
• Ulfhammer G, Edén A, Mellgren Å, et al. Persistent CNS immune activation following more than 10 years of effective HIV antiretroviral treatment. AIDS. 2018;32(15):2171–2178.
   PubMed Web of Science ®Google Scholar
• Hagberg L, Cinque P, Gisslen M, et al. Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther. 2010;3:15.
   Google Scholar
• Cysique LAJ, Maruff P, Darby D, et al. The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol. 2006;21(2):185–194.
   PubMed Web of Science ®Google Scholar
• Maruff P, Thomas E, Cysique L, et al. Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol. 2009;24(2):165–178.
   PubMed Web of Science ®Google Scholar
• Bloch M, Kamminga J, Jayewardene A, et al. A screening strategy for HIV-associated neurocognitive disorders that accurately identifies patients requiring neurological review. Clin Infect Dis. 2016;63(5):687–693.
   PubMed Web of Science ®Google Scholar
• Best BM, Letendre SL, Koopmans P, et al. Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, Tenofovir. J Acquir Immune Defic Syndr. 2012;59(4):376–381.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Bonora S, Simiele M, et al. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. AIDS. 2011;25(11):1437–1439.
   PubMed Web of Science ®Google Scholar
• Ocque AJ, Hagler CE, Morse GD, et al. Development and validation of an LC–MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal. 2018;156:163–169.
   PubMed Web of Science ®Google Scholar
• Hsue PY, Hunt PW, Wu Y, et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients. AIDS. 2009;23(15):2021–2027.
   PubMed Web of Science ®Google Scholar
• Wang X, Chai H, Lin PH, et al. Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells. Am J Pathol. 2009;174(3):771–781.
   PubMed Web of Science ®Google Scholar
• De Pablo C, Orden S, Calatayud S, et al. Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment. Antivir Ther. 2012;17(8):1615–1619.
   PubMed Web of Science ®Google Scholar
• Alvarez A, Orden S, Andújar I, et al. Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS. 2017;31(13):1781–1795.
   PubMed Web of Science ®Google Scholar
• Van Zoest RA, Underwood J, De Francesco D, et al. Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers. J Infect Dis. 2018;217(1):69–81.
   Web of Science ®Google Scholar
• Dahl V, Peterson J, Fuchs D, et al. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS. 2014;28(15):2251–2258.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Price RW, Spudich S, et al. Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47(2):168–173.
   PubMed Web of Science ®Google Scholar